Health TrialsbyHealthPanel

Feedback Loop Between Intracranial Atherosclerosis and Cerebral Small Vessel Disease

ConditionsICAS - Intracranial AtherosclerosisCerebral Small Vessel Diseases
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age30+
SponsorChinese PLA General Hospital

About this trial

The present study aims at verifying the mutual effects between intracranial large artery atherosclerosis and cerebral small vessel disease on disease progression and prognosis by magnetic resonance imaging, and providing biomarkers for the early prevention and treatment of cerebrovascular disease.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age ≥ 18 years

At least one intracranial artery ≥ 50% atherosclerotic stenosis

Modified Rankin Scale < 2

Mini-mental State Examination > 24

Disqualifiers

Concurrent ipsilateral extracranial artery ≥ 50% stenosis

Pregnant women

Contraindications to magnetic resonance examination (patients with pacemakers, nerve stimulators, artificial metal heart valves and other metal foreign bodies)

Trial population

Participants with at least on intracranial artery ≥ 50% atherosclerotic stenosis.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Magnetic resonance imaging

    Diagnostic test

    Imaging diagnostics mainly based on Magnetic resonance imaging.

Treatment groups

300 Participants
are divided into 1 treatment group
Group A: Intracranial atherosclerosis and small vessel disease1 intervention

Trial outcomes

Primary outcomes

1

Progression in total cerebral small vessel disease burden

Total cerebral small vessel disease burden is assessed according to a sum of scores of white matter hyperintensity, cerebral microbleeds, lacunes and enlarged perivasular spaces on magnetic resonance imaging sequences.

Time frame
1-3 YEARS
2

Frequency of stroke recurrence

The percentage of symptomatic participants who suffer from stroke recurrence after enrollment in the territory of the targeted stenotic vessel.

Time frame
1-3 YEARS

Secondary outcomes

1

Frequency of stroke of asymptomatic participants

The percentage of asymptomatic participants who suffer from stroke after enrollment in the territory of the targeted stenotic vessel.

Time frame
1-3 YEARS

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Chinese PLA General Hospital

Lead sponsor

Source ClinicalTrials.gov
Apply now